Glargine U300 Insulin in Diabetes Care
Dr. G Vijay Kumar, practicing diabetes management in Chennai, emphasizes the shift from traditional glycaemic control measures to a more comprehensive approach. Beyond fasting and postprandial glucose levels, key components now include hypoglycaemia, glycaemic variability, and Time in Range (TIR). Improving TIR and reducing glycaemic variability while minimizing hypoglycaemia can significantly enhance a patient's quality of life.
Insulin Glargine U300, with its distinct pharmacokinetic and pharmacodynamic profiles, offers a longer duration of action—up to 36 hours—compared to U100, improving predictability. ATOS study, a real-world study with Indian patients, confirms that U300 is both effective and safe for insulin-naïve type 2 diabetes patients. U300 provides flexible injection timing with a ±3-hour window, totalling a 6-hour period. It is not only safe and effective for regular patients but also for vulnerable populations, including the elderly, those with chronic kidney disease (CKD), and during pregnancy.
I am Dr. G Vijay Kumar practicing diabetes management in Chennai. Let me extend my cardio vicious and greetings to you all as the entire world has moved from glycemic trial to a headset. Apart from fasting, post-prenade HVAMC which forms a trial, glycemic trial, we also have to include hypoglycemia, glycemic variability and implementing time and range, which you call TIR. And these three are a very, very important components of the headset because the quality of life, if you improve the TIR and if you reduce the glycemic variability, if you minimize hypoglycemia, the quality of life for the patient is going to improve enormously. U 300, largely different PKPD that is pharmacokinetics and pharmacodynamic profiles. Now you can see that this particular U 300 compared to U 100 has got a longer duration of action up to 36 hours and mind you, longer the duration of the basal insulin, the predictability of action improves. Atlas is a study, which is a real world study with Indian patients, confirms that U 300 insulin is effective and safe in insulin-9 type 2 diabetic patients. There is a flexibility injection time means, plus or minus 3 hours, a total of 6 hours of window period is available, apart from gender and ACN safety. It is also efficacious and safe in various populations, especially vulnerable populations such as elderly, CKD and pregnancy. And this is apart from the safety and efficacy in our regular diabetic patients or please whom we see in a regular practice. Now friends, with all the proven efficacy, safety and apart from the most important, fast effectiveness compared to the other basic insulin, thank you very much.
Dr. G Vijay Kumar, practicing diabetes management in Chennai, emphasizes the shift from traditional glycemic control measures to a more comprehensive approach. Beyond fasting and postprandial glucose levels, key components now include hypoglycemia, glycemic variability, and Time in Range (TIR). Improving TIR and reducing glycemic variability while minimizing hypoglycemia can significantly enhance a patient's quality of life.
Insulin Glargine U300, with its distinct pharmacokinetic and pharmacodynamic profiles, offers a longer duration of action—up to 36 hours—compared to U100, improving predictability. The Atlas study, a real-world study with Indian patients, confirms that U300 is both effective and safe for insulin-naïve type 2 diabetes patients. U300 provides flexible injection timing with a plus-minus three-hour window, totaling a six-hour period. It is not only safe and effective for regular patients but also for vulnerable populations, including the elderly, those with chronic kidney disease (CKD), and during pregnancy.
